Corporate Philanthropy - Best Practices at Novartis AG

<< Previous

Excerpts

Malaria affects poor people and children in many African and Asian countries. Every year, at least one million children die due to malaria in this region. As most of the sufferers were poor people from underdeveloped countries, global pharma companies did not pay much attention to research on drugs against malaria. The total expenditure on malaria related R&D was around US$323 million in 2004. The incidence of malaria increased from the 1980s mainly due to the increased resistance to drugs that had earlier been effective...

Another area where the Novartis Foundation undertook substantial work was in the cause related to AIDS orphans. These children required emotional and social support apart from medical support. Children with AIDS were treated as outcasts by society, especially in the African and Asian countries...

Tropical diseases were often not given enough importance by pharmaceutical companies. Only 1% of the 1,400 new drugs introduced between 1975 and 1999 were meant for tropical diseases. In order to address this problem, Novartis established a research institute, the Novartis Institute for Tropical Diseases (NITD) in Singapore in 2002...

Exhibit I: UN Global Compact Principles
Exhibit II: Novartis - 'Access to Medicine' Projects
Exhibit III: Novartis Foundation - Vision, Mission, Objectives
Exhibit IV: Novartis - Mergers & Acquisitions (1997-2005)
Exhibit V: Projects of Novartis Foundation
Exhibit VI: Novartis Code of Conduct
Exhibit VII: Novartis - Policy on Corporate Citizenship

---

Custom Search

---

Business Ethics and Corporate Governance Textbook Textbooks Collection	Business Ethics and Corporate Governance Workbook Workbooks Collection	Case Studies in Business Ethics - Vol. I Case Study Volumes Collection